2015 Press Releases


Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 17, 2015
Xenon and Genentech Publish in Science the 3-D Crystal Structure of a Novel Nav1.7 Compound Binding Site Enabling the Development of Potent Selective Inhibitors to Treat Pain
BURNABY, British Columbia, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced publication of a key article in Science by researchers at Xenon and Genentech describing for the first time the X-ray crystal structure... More >>
November 12, 2015
Xenon Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference
BURNABY, British Columbia, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel 2015 Healthcare Con... More >>
November 10, 2015
Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Progress Includes Initiation of XEN801 Phase 1 Clinical Trial and Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Genetics Collaboration Conference Call/Webcast Today at 5:00 p.m. Eastern Time BURNABY, British Columbia, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmace... More >>
November 5, 2015
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 third quarter financial and operating results after the close of U.S. financial markets on Tuesday, November ... More >>
October 22, 2015
Xenon Announces Its Partner Genentech Has Advanced GDC-0310, a Second Nav1.7 Inhibitor for Pain, Into Clinical Development
BURNABY, British Columbia, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the Company's partner Genentech, a member of the Roche Group, has advanced a second Nav1.7 inhibitor into clinical development. GDC-... More >>
September 24, 2015
Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial
Phase 2 in Acne Patients Expected to be Initiated by Year-End BURNABY, British Columbia, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of its lead proprietary progra... More >>
September 21, 2015
Xenon Pharmaceuticals Achieves Milestone in Genentech Collaboration to Discover Novel Pain Targets
BURNABY, British Columbia, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the Company has achieved a milestone in its pain genetics discovery collaboration with Genentech, a member of the Roche Group, trig... More >>
September 3, 2015
Xenon Pharmaceuticals to Present at the 10th Annual Wells Fargo Healthcare Conference
BURNABY, British Columbia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the 10th Annual Wells Fargo He... More >>
August 10, 2015
Xenon Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Continued Pipeline Progress in Partnered and Proprietary Programs; Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today reported its f... More >>
August 6, 2015
Xenon Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference
BURNABY, British Columbia, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Canaccord Genuity 35th Annu... More >>
August 5, 2015
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 second quarter financial and operating results after the close of U.S. financial markets on Monday, August 10... More >>
July 1, 2015
Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss TV-45070 Phase 2b Study in Osteoarthritis Pain
BURNABY, British Columbia, July 1, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) today to discuss the TV-45070 Phas... More >>
July 1, 2015
Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain
TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints in Phase 2b study in pain due to osteoarthritis of the knee. TV-45070 demonstrated a favorable safety and tolerability profile, with no drug-related serious adverse events. Low... More >>
May 28, 2015
Xenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
BURNABY, British Columbia, May 28, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a business update, including progress toward mileston... More >>
May 22, 2015
Xenon Pharmaceuticals Appoints Steven Gannon to Its Board of Directors
BURNABY, British Columbia, May 22, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Steven Gannon has been appointed to its Board of Directors, where he will also serve on the Company's Audit Committee. Mr. Gannon is ... More >>
May 12, 2015
Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
Continued Pipeline Progress in Partnered and Proprietary Programs Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, May 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its fina... More >>
May 7, 2015
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2015 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 7, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2015 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 12, 20... More >>
April 2, 2015
Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (PHN)
JERUSALEM and BURNABY, British Columbia, April 2, 2015 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:XENE) today announced that the first patient has been enrolled into the Phase 2b study designed to evaluate the safety and eff... More >>
March 16, 2015
Xenon Pharmaceuticals Appoints Dr. Richard H. Scheller to Its Board of Directors
BURNABY, British Columbia, March 16, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Richard H. Scheller, Ph.D., has been appointed to its Board of Directors. Dr. Scheller is a globally recognized leader in biomedica... More >>
March 12, 2015
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
Progress in Partnered Programs and Proprietary Development Pipeline Conference Call/Webcast Today at 4:30 p.m. Eastern Time BURNABY, British Columbia, March 12, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its f... More >>
March 9, 2015
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2014 Financial Results and Provide Corporate Update
BURNABY, British Columbia, March 9, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2014 financial and operating results after the close of U.S. financial markets on Thursday, March 12, 2015. Xenon... More >>
February 19, 2015
Xenon Pharmaceuticals' Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
Clinical Program in Post-Herpetic Neuralgia Broadens Opportunity of TV-45070 Into Neuropathic Pain BURNABY, British Columbia, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that its development and commercializ... More >>
January 8, 2015
Xenon Pharmaceuticals Outlines Key Anticipated Milestones for 2015
Partnered Programs on Track; Proprietary Development Pipeline Progressing; Multiple Potential Near-Term Milestones BURNABY, British Columbia, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated 2015 mi... More >>